Contents

Search

botulinum antitoxin

Indications: - treatment of naturally occurring noninfant botulism Mechanism of action: - equine-derived antibody to the 7 known botulinum toxin types (A-G) - composed of <2% intact immunoglobulin G (IgG) & >=90% Fab & F(ab')2 immunoglobulin fragments - Fab & F(ab')2 fragments are cleared from circulation more rapidly than intact IgG1) - repeat HBAT dosing might be indicated for some wound or intestinal colonization patients if in situ botulinum toxin production continues after clearance of antitoxin - does NOT reverse existent paralysis [3] Notes: - available only from CDC

Related

botulism

General

antitoxin (passive immunizing agent, immune serum)

References

  1. Centers for Disease Control and Prevention (CDC) Investigational Heptavalent Botulinum Antitoxin (HBAT) to Replace Licensed Botulinum Antitoxin AB and Investigational Botulinum Antitoxin E Morbidity and Mortality Weekly Report (MMWR) 2010, 59(10);299 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5910a4.htm
  2. FDA News Release: March 22, 2013 FDA approves first Botulism Antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm
  3. Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
  4. CDC's botulism treatment program http://www.bt.cdc.gov/agent/botulism